Sinclair Pharma PLC Hardman Research: Promising start in the US
July 12 2017 - 1:15AM
RNS Non-Regulatory
TIDMSPH
Sinclair Pharma PLC
12 July 2017
Hardman Research: Promising start in the US
Promising start in the US - In 2016 Sinclair was transformed
into a streamlined, pure-play aesthetics company with a
concentrated, highly competitive, portfolio of differentiated
injectable products. Effective, longer-lasting, natural looking,
minimally invasive treatments are benefiting from the trend away
from intensive plastic surgery and represent a major growth
opportunity. Products are sold directly in Europe and Brazil, and
via distributors elsewhere globally. In a detailed trading
statement, sales progress of products has been compared to the
strong in-market demand, which augurs well for the full year.
Silhouette InstaLift is continuing to gain sales traction in the
US.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/sinclair-pharma-plc-documents/12.07.17-promising-start-in-the-us.pdf
To contact us: Contacts:
Hardman & Co Dr Martin Hall
35 New Broad Street mh@hardmanandco.com
London Dr Dorothea Hill
EC2M 1NH dmh@hardmanandco.com
www.hardmanandco.com Dr Gregoire Pave
Follow us on Twitter gp@hardmanabdco.com
@HardmanandCo Telephone: +44 20 7194
7622
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKDDNPBKDAOD
(END) Dow Jones Newswires
July 12, 2017 02:15 ET (06:15 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Apr 2024 to May 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2023 to May 2024